{"url_path":"/sec/aqst/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1398733/0001398733-26-000041-index.html","accession_number":"0001398733-26-000041","cik":"0001398733","ticker":"AQST","issuer_name":"Aquestive Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1398733/0001398733-26-000041-index.html","primary_entity_key":"0001398733","primary_entity_name":"Aquestive Therapeutics, Inc."},"word_count":149,"has_tables":true,"body_markdown":"Item 2.02\n\nResults of Operations and Financial Condition.\n\nOn August 11, 2026, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the second quarter ended June 30, 2026 and provided an update on recent developments in its business. A copy of the Company’s press release and the attached financial schedules are attached as Exhibit 99.1 to this Current Report On Form 8-K and incorporated in this Item 2.02 by reference.\n\nThe information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of, or otherwise subject to the liabilities of Section 18 of the Exchange Act,nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing."}